Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oculus Innovative Sciences launches Microcyn

This article was originally published in The Gray Sheet

Executive Summary

Firm debuts the skin and wound cleaner in both professional and over-the-counter versions Aug. 18. The former product is indicated for debridement of wounds like stage I-IV pressure ulcers, diabetic foot ulcers, post-surgical wounds and first- and second-degree burns, while the OTC version is indicated for use in cleansing dirt and debris from lacerations, skin abrasions, minor burns and minor skin irritations. The product, which received 510(k) clearance in May, is effective against a broad spectrum of gram-positive, gram-negative and yeast species, according to the Petaluma, Calif., company. Oculus also will introduce a Microcyn hydrogel OTC formulation in October, followed by a full launch to medical professionals in 2010, the company says
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT027825

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel